Merck & Co (MRK)
$126.45
0.60 (0.48%)
MRK Stock Quote Delayed 30 Minutes
The New Nifty Fifty
Long-term investors may find opportunities in this group of largely household names -- with steady earnings and often above-average dividends.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
320.09B
PE Ratio
140.50
EPS
0.9
Volume (Avg. Vol.)
6.79M
Day's Range
$124.91 - $126.60
52-Week Range
$99.14 - $134.63
Dividend & Yield
$2.92 (2.31%)
MRK Stock Predictions, Articles, and Merck & Co News
Look What’s Up When the Market’s Are Down
Despite a down day Thursday consumer, pharmaceutical and utility ETF's did very well and investors may want to look at the sectors for investment
Investors Bag the Groceries: Thursday’s IP Market Recap
Markets were down as continued worries about Europe and another round of disappointing earnings and guidance pushed prices lower.
4 ETFs to Guard Against Market Volatility
Worried about the market's current uncertainty? A good defensive play right now is low-risk, low-beta ETFs. Here are four of the best.
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome.
Dividends Do Matter in Dud Stocks
For those investors watching their investments lose ground, the dividends really do matter. But ... stock appreciation should make your checklist, too.
What’s the Real Impact of Generic Drugs?
The danger of patent expirations for big pharma isn't new, but the amount of market share those brands are losing to generics as a result are not pretty.
Don’t Buy Pharma Stocks — Buy THESE Pharma Stocks
If your sliver of the pharma pie is too small, it's easy to fall into the "any old pharma stock will do" trap. Keep your eye on the prize with these must-own names.
Top 10 Dow Dividend Stocks
Long-term investors can reap income -- and a little peace of mind -- with these risk-off plays with juicy dividend yields. Here are 10 DJIA names to consider.
Top 10 Dow Dividend Stocks
Just in time for summer, we've got market volatility! Investors wanting to shrug off the headlines should consider piling into these elite Dow income stocks.
Gilead Sciences’ HIV Drugs Clear a Hurdle
Full FDA approval should come next -- but if not, watch out, because Gilead is very heavily dependent on its HIV drug lineup, and patents will be expiring.
Obesity: The Next Investment Driver
The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.
Pfizer is Still a Pharmaceutical-Giant Buy
Despite a slowdown in sales as Lipitor becomes a generic drug, pharma giant Pfizer is still a very good buy, and a great play for your portfolio.
10 Stocks to Watch Get Ready to Release Earnings
Earnings releases from 10 key stocks can effect your portfolio decisions, so keep an eye on them over the next two days.
3 Ways to Buy Into a German Recovery
Germany's political machine has a lot to chew through in the next two years of elections, but these three stocks get my vote -- regardless of who wins.
Should I Buy Johnson & Johnson? 3 Pros, 3 Cons
Johnson & Johnson (JNJ) is off to a slow start in 2012, and its recent earnings report didn't do much to rouse the sleeping giant. Are JNJ shares worth buying?
Top 10 Dow Dividend Stocks for Retirement Investors
Anyone with a retirement portfolio should pay attention to Wall Street's elite group of blue-chip dividend stocks.
4 New ETFs: They’re All About Income
Last week's launches aimed straight at the income-investing crowd -- and included both equity funds of high dividend payers and a high-yield bond fund.
Why Investors Needn’t Fear the ‘Patent Cliff’
Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance.
Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World
Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends.
10 Pharma Blue Chips to Buy
There are a number of great companies in pharma if you know where to look.
